NEW YORK, Nov. 2, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will participate in an event to celebrate the newest advancements in regenerative medicine on November 9th, 2010 in Walkersville, MD.
Regenicin will present their role in the commercialization of the therapeutic candidate, PermaDerm™, a product which could help revolutionize the way wounded warriors and civilians recover from severe burns and wounds. Speaking on behalf of Regenicin will be Dr. Craig Eagle, a member of Regenicin's Board of Directors, and head of Oncology for Pfizer Worldwide.
The event will be hosted by Lonza Walkersville, Inc. a subsidiary of Lonza AG, a Swiss based life science company and one of the world's leading cell therapy manufacturers. Also scheduled to participate in the event are the Armed Forces Institute of Regenerative Medicine, the U.S. Department of Defense Office of Technology Transition; as well as members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons on the frontlines of treating burns and wounds in the U.S.
PermaDerm™ is the only tissue-engineered skin prepared from autologous (patient's own) skin cells from both the epidermal and dermal skin layers. A small sample of the patient's skin can be expanded in the laboratory to cover a wound site that extends over 50% of the patient's body. These self-to-self skin grafts are intended to form permanent wound closure that is not rejected by the patient's immune system, a critical possibility in porcine or cadaver skin grafts used today.
About Regenicin, Inc.
Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly trade
|SOURCE Regenicin(TM), Inc.|
Copyright©2010 PR Newswire.
All rights reserved